Methanesulfonate crystal form of a compound, pharmaceutical composition and use

CN116120301BActive Publication Date: 2024-11-05SHENZHEN KEYE HEALTH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211413921.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-11
Publication Date
2024-11-05
Estimated Expiration
2042-11-11

AI Technical Summary

Technical Problem

由于DHX33的蛋白功能依赖于其解旋酶活力,而DHX33的解旋酶活力缺失突变体不具有DHX33蛋白的功能,因而无法替代野生型DHX33基因所编码的蛋白功能

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003939039440000011
    Figure BDA0003939039440000011
  • Figure BDA0003939039440000061
    Figure BDA0003939039440000061
  • Figure BDA0003939039440000071
    Figure BDA0003939039440000071
Patent Text Reader

Abstract

The present invention relates to a mesylate crystal form of a compound, a pharmaceutical composition and uses, and specifically to different crystal forms of the mesylate of 1-(3-cyano-5-methylthiophene-2-yl)-N-(6-methoxy-1H-benzo[d]imidazol-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxamide, a pharmaceutical composition containing the crystal form and uses.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemistry, and relates to different crystal forms of the mesylate of 1-(3-cyano-5-methylthiophene-2-yl)-N-(6-methoxy-1H-benzo[d]imidazol-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxamide (hereinafter referred to as "the compound of formula (1)"), and also relates to a pharmaceutical composition containing the crystal form and its medical use. Background Art

[0002] DHX33 belongs to the RNA helicase protein family containing the DEAD / H box. DEAD / H stands for the amino acid abbreviation Asp-Glu-Ala-Asp / His. This sequence, together with several other conserved amino acid sequences, appears in the protein sequences of members of the RNA helicase family and is highly involved in nucleic acid substrate binding and ATP hydrolysis. Although these family members share these same sequences, each RNA helicase has its own specific specificity and unique biological function. The molecular weight of human DHX33 protein is 72kDa. It has the function of unwinding nucleic acids. It uses the bioenergy released by ATP hydrolysis to drive the change of the conformation of RNA and protein complexes, and then participates in a variety of RNA metabolic activities, specifically, a series of biological processes from RNA transcription, shearing, editing, translation to degradation. The function of DHX33 is not limited to the modification of RNA molecules. Studies have shown that in addition to unwinding RNA double strands, DHX33 protein is also involved in DNA metabolism. Specifically, DHX33 protein can unwind the double-stranded structure of DNA and play an important role in gene expression.

[0003] Studies have shown that DHX33 affects the methylation state of DNA by binding to the promoters of genes related to various cancers, thereby regulating the expression of various cancer genes and signal pathways related to tumor development at the genomic level, and plays a vital role in various cell activities such as cell growth, proliferation, migration, apoptosis, and metabolism. In addition, it was found that DHX33 can sense the invasion of foreign double-stranded RNA molecules and play an important role in the innate immunity of cells. As a very important cell growth regulatory gene, DHX33 is highly expressed in many cancers, such as lung cancer, lymphoma, glioblastoma, breast cancer, colon cancer, liver cancer, etc. The occurrence and development of many cancers depend on the high expression of DHX33 protein. Genetic knockout of DHX33 can significantly inhibit the occurrence and development of lung cancer driven by RAS oncogene; in vivo and in vitro experiments have confirmed that after inhibiting DHX33 protein, the occurrence and development of various cancers such as breast cancer, colon cancer, brain glioma, lymphoma, etc. are significantly inhibited. Since the protein function of DHX33 depends on its helicase activity, and the helicase activity-deficient mutant of DHX33 does not have the function of DHX33 protein, it cannot replace the function of the protein encoded by the wild-type DHX33 gene.

[0004] The applicant has discovered a variety of compounds that can inhibit the RNA helicase activity of DHX33 (for example, 1-(3-cyano-5-methylthiophene-2-yl)-N-(6-methoxy-1H-benzo[d]imidazol-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxamide), and verified that these compounds can significantly inhibit the growth and proliferation of cancer cells both in vitro and in vivo. Summary of the invention

[0005] The object of the present invention is to provide different crystalline forms of 1-(3-cyano-5-methylthiophene-2-yl)-N-(6-methoxy-1H-benzo[d]imidazol-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxamide (hereinafter referred to as "compound of formula (1)") methanesulfonate, pharmaceutical compositions containing the crystalline forms, and uses.

[0006] The structural formula of the compound of formula (1) is as follows:

[0007]

[0008] In a first aspect, the present invention provides a mesylate salt form B of the compound of formula (1), whose X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at the following 2θ angles: 8.88±0.2°, 14.85±0.2° and 15.35±0.2°.

[0009] In some embodiments, the X-ray powder diffraction pattern of the mesylate salt form B of the compound of formula (1) also has characteristic diffraction peaks at one or more of the following 2θ angles: 21.33±0.2°, 21.57±0.2° and 21.99±0.2°.

[0010] In some embodiments, the X-ray powder diffraction pattern of the mesylate salt form B of the compound of formula (1) also has characteristic diffraction peaks at one or more of the following 2θ angles: 7.66±0.2°, 18.84±0.2° and 23.13±0.2°.

[0011] The present invention also provides a method for preparing the mesylate crystal form B of the compound of formula (1), comprising: adding an organic solvent to the free crystal form A of the compound of formula (1), then adding methanesulfonic acid, stirring at room temperature for about 2-5 days, collecting the solid and then drying to obtain the mesylate crystal form B; the organic solvent is selected from isopropanol, acetone, ethyl acetate, acetonitrile, tetrahydrofuran or dichloromethane.

[0012] In some embodiments, in the above preparation method, drying is performed under vacuum at 40-95° C. for about 8-16 hours.

[0013] In a second aspect, the present invention provides a mesylate salt form C of the compound of formula (1), whose X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at the following 2θ angles: 8.07±0.2° and 15.17±0.2°.

[0014] In some embodiments, the X-ray powder diffraction pattern of the mesylate crystalline form C of the compound of formula (1) also has characteristic diffraction peaks at one or more of the following 2θ angles: 12.64±0.2°, 23.51±0.2° and 24.47±0.2°.

[0015] In some embodiments, the X-ray powder diffraction pattern of the mesylate crystalline form C of the compound of formula (1) also has characteristic diffraction peaks at one or more of the following 2θ angles: 7.17±0.2°, 8.63±0.2° and 17.34±0.2°.

[0016] The present invention also provides a method for preparing the mesylate crystal form C of the compound of formula (1), comprising any one of the following methods:

[0017] (I) adding water or a mixed solvent of water / organic solvent to the mesylate crystalline form B of the compound of formula (1), and stirring at room temperature for about 2-5 days to obtain the mesylate crystalline form C, wherein the organic solvent is selected from ethanol or 1,4-dioxane, and the volume ratio of water to the organic solvent in the mixed solvent is 1:1.

[0018] (II) adding a mixed solvent of water / organic solvent to the mesylate salt form B of the compound of formula (1), stirring at 4-8° C. for about 2-5 days to obtain the mesylate salt form C, wherein the organic solvent is selected from methanol, n-propanol, acetonitrile or acetone, and the volume ratio of water to the organic solvent in the mixed solvent is 1:1 to 3:1.

[0019] (III) adding a mixed solvent of water / organic solvent to the mesylate salt form B of the compound of formula (1), stirring at 50° C. for about 2-5 days to obtain the mesylate salt form C, wherein the organic solvent is selected from isopropanol or tetrahydrofuran, and the volume ratio of water to the organic solvent in the mixed solvent is 1:1.

[0020] In a third aspect, the present invention provides a mesylate salt form F of the compound of formula (1), whose X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at the following 2θ angles: 9.60±0.2°, 18.39±0.2° and 19.48±0.2°.

[0021] In some embodiments, the X-ray powder diffraction pattern of the mesylate crystalline form F of the compound of formula (1) also has characteristic diffraction peaks at one or more of the following 2θ angles: 27.94±0.2°, 28.27±0.2° and 28.73±0.2°.

[0022] In some embodiments, the X-ray powder diffraction pattern of the mesylate crystalline form F of the compound of formula (1) also has characteristic diffraction peaks at one or more of the following 2θ angles: 5.88±0.2°, 12.47±0.2° and 37.34±0.2°.

[0023] The present invention also provides a method for preparing the mesylate crystal form F of the compound of formula (1), comprising: adding a mixed solvent of water / methanol to the mesylate crystal form B of the compound of formula (1), promoting dissolution, and then filtering, and stirring the filtrate at 5° C. for about 2-24 hours to obtain the mesylate crystal form F, wherein the volume ratio of water to methanol in the mixed solvent is 1:3 to 1:5.

[0024] In some embodiments, in the above preparation method, the dissolution promoting is performed by increasing the temperature to 50°C, ultrasound, prolonged stirring or vortex conditions.

[0025] In some embodiments, in the above preparation method, the volume ratio of water to methanol in the mixed solvent is 1:3.

[0026] In some embodiments, in the above preparation method, the volume ratio of water to methanol in the mixed solvent is 1:5.

[0027] In a fourth aspect, the present invention provides a pharmaceutical composition comprising at least one of the above-mentioned crystal forms and one or more pharmaceutically acceptable carriers.

[0028] In a fifth aspect, the present invention provides use of the above-mentioned crystal form or the above-mentioned pharmaceutical composition in the preparation of a medicament for preventing and / or treating a disease or condition at least partially mediated by DHX33.

[0029] In a sixth aspect, the present invention provides a method for preventing and / or treating a disease or condition at least partially mediated by DHX33, comprising the following steps: administering a preventive and / or therapeutically effective amount of the above-mentioned crystalline form or the above-mentioned pharmaceutical composition to an individual in need thereof; preferably, the disease is selected from cancer, viral infection and inflammation mediated by DHX33.

[0030] The present invention is not to be limited to the particular embodiments described herein; it is also to be understood that the terminology used herein is for the purpose of describing only and not limiting of particular embodiments.

[0031] Definition of terms

[0032] Unless otherwise stated, the technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. If there is a contradiction, the definition provided by the application shall prevail. When a certain amount, concentration or other value or parameter is expressed in the form of a range, a preferred range or a preferred upper numerical limit and a preferred lower numerical limit, it should be understood that it is equivalent to specifically disclose any scope by combining any pair of upper range limits or preferred values ​​with any lower range limit or preferred values, without considering whether the scope is specifically disclosed. Unless otherwise stated, the numerical range listed herein is intended to include all integers and fractions (decimals) within the endpoints and the range of the range.

[0033] The term "about" when used with a numerical variable generally refers to the value of that variable and all values ​​of that variable are within experimental error (eg, within a 95% confidence interval for the mean) or within ±10% of the specified value, or wider.

[0034] The expression "comprising" or its synonymous similar expressions "including", "containing" and "having" etc. are open-ended and do not exclude additional unrecited elements, steps or ingredients. The expression "consisting of excludes any element, step or ingredient not specified. The expression "consisting essentially of means that the scope is limited to the specified elements, steps or ingredients, plus the optional elements, steps or ingredients that do not materially affect the basic and novel characteristics of the claimed subject matter. It should be understood that the expression "comprising" encompasses the expressions "consisting essentially of" and "consisting of".

[0035] The term "X-ray powder diffraction pattern (XRPD pattern)" refers to an experimentally observed diffraction pattern or a parameter, data or value derived therefrom. An XRPD pattern is usually characterized by peak positions (abscissa) and / or peak intensities (ordinate).

[0036] The term "diffraction angle" or "2θ" refers to the peak position expressed in degrees (°) based on the setup in the X-ray diffraction experiment, and is usually the unit of the abscissa in the diffraction pattern. If the reflection is diffracted when the incident beam forms an angle θ with a certain lattice plane, the experimental setup requires that the reflected beam be recorded at an angle of 2θ. It should be understood that the specific 2θ value mentioned in this article for a specific crystal form is intended to represent the 2θ value (expressed in degrees) measured using the X-ray diffraction experimental conditions described herein.

[0037] It should be noted that in the powder X-ray diffraction spectrum, the position of the peak or the relative intensity of the peak may vary due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, there may be an error in the position of the peak, and the measurement error of the 2θ value may be ±0.2°. Therefore, when determining each crystal form, this error should be taken into account, and the error is also within the scope of this application.

[0038] For the same crystal form, the position of the endothermic peak of DSC may be different due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, the position of the endothermic peak may have an error, which may be ±5°C or ±3°C. Therefore, when determining each crystal form, this error should be taken into account, and the error is also within the scope of this application.

[0039] For the same crystal form, the position of the weight loss temperature of TGA may be different due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, there may be an error in the position of the weight loss temperature, which may be ±5°C or ±3°C. Therefore, when determining each crystal form, this error should be taken into account, and the error is also within the scope of this application.

[0040] It should be understood that different types of equipment or using different test conditions may give slightly different XRPD patterns and characteristic peaks or different DSC patterns and characteristic peaks. The specific values ​​provided are not to be taken as absolute values.

[0041] The term "room temperature" refers to 20°C ± 5°C.

[0042] The term "prevention" refers to prophylactic administration to reduce the likelihood of or delay the onset of a disease or symptom.

[0043] The term "treatment" aims to alleviate or eliminate the disease state or condition being targeted. It should also be understood that the treatment of the disease state or condition includes not only complete treatment, but also less than complete treatment, but achieving some biological or medically relevant results.

[0044] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or crystal forms that are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reaction or other problems or complications, and are commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment. "Pharmaceutically acceptable carrier" refers to an inert substance that is administered together with the active ingredient and is conducive to the administration of the active ingredient, including but not limited to any glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, disintegrant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier that is acceptable for human or animal (e.g., livestock) approved by the State Food and Drug Administration.

[0045] The above-mentioned pharmaceutical compositions can act systemically and / or locally. For this purpose, they can be administered by suitable routes, for example, by parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intradermal, percutaneous, rectal, intracranial, intraperitoneal, intranasal, intramuscular routes or as inhalant administration.

[0046] The above-mentioned administration route can be achieved through a suitable dosage form. The dosage forms that can be used in the present invention include, but are not limited to, tablets, capsules, lozenges, hard candies, powders, sprays, creams, ointments, suppositories, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, etc.

[0047] When administered orally, the pharmaceutical composition can be prepared into any orally acceptable preparation form, including but not limited to tablets, capsules, aqueous solutions, aqueous suspensions, and the like.

[0048] The term "disease or condition mediated at least in part by DHX33" refers to a disease whose pathogenesis at least partially involves factors related to DHX33, such as cancer, viral infection, and inflammation.

[0049] The term "effective amount" refers to a dose that can induce a biological or medical response in cells, tissues, organs or organisms (eg, individuals) and is sufficient to achieve the desired preventive and / or therapeutic effect.

[0050] The therapeutically effective amount of the crystalline form described herein is from about 0.0001 to 20 mg / Kg body weight / day, for example, from 0.001 to 10 mg / Kg body weight / day.

[0051] The dosage frequency of the crystal form described in the present application is determined by the needs of individual patients, for example, once or twice a day, or more times a day. Administration can be intermittent, for example, wherein during a period of several days, the patient receives a daily dose of the crystal form, and then during a period of several days or more days, the patient does not receive a daily dose of the crystal form. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] Figure 1 : X-ray powder diffraction (XRPD) pattern of free crystalline form A of the compound of formula (1).

[0053] Figure 2 : Thermogravimetric analysis (TGA) diagram of free crystalline form A of the compound of formula (1).

[0054] Figure 3 : Differential scanning calorimetry (DSC) diagram of free crystalline form A of the compound of formula (1).

[0055] Figure 4 : The free form of the compound of formula (1) 1 H NMR spectra.

[0056] Figure 5 : X-ray powder diffraction (XRPD) pattern of mesylate crystalline form A of the compound of formula (1).

[0057] Figure 6 : Thermogravimetric analysis (TGA) of the mesylate form A of the compound of formula (1).

[0058] Figure 7 : Differential scanning calorimetry (DSC) diagram of the mesylate crystal form A of the compound of formula (1).

[0059] Figure 8 : X-ray powder diffraction (XRPD) pattern of mesylate form B of the compound of formula (1).

[0060] Fig. 9 : Thermogravimetric analysis (TGA) of the mesylate crystal form B of the compound of formula (1).

[0061] Fig.10 : Differential scanning calorimetry (DSC) diagram of the mesylate crystal form B of the compound of formula (1).

[0062] Fig.11 : The mesylate crystal form B of the compound of formula (1) 1 H NMR spectra.

[0063] Fig.12 : X-ray powder diffraction (XRPD) pattern of mesylate crystal form C of the compound of formula (1).

[0064] Fig.13 : XRPD comparison diagram of the mesylate crystal form C of the compound of formula (1) before and after heating.

[0065] Fig.14 : X-ray powder diffraction (XRPD) pattern of the mesylate crystalline form L of the compound of formula (1).

[0066] Fig.15 : XRPD comparison diagram of the mesylate crystal form L of the compound of formula (1) before and after standing at room temperature.

[0067] Fig.16 : Thermogravimetric analysis (TGA) of the mesylate crystal form C of the compound of formula (1).

[0068] Fig.17 : Differential scanning calorimetry (DSC) diagram of mesylate crystal form C of the compound of formula (1).

[0069] Fig.18 : X-ray powder diffraction (XRPD) pattern of mesylate crystalline form D of the compound of formula (1).

[0070] Fig.19 : XRPD comparison diagram of the mesylate salt form D of the compound of formula (1) before and after drying at 40°C.

[0071] Fig. 20 : X-ray powder diffraction (XRPD) pattern of the mesylate crystalline form D1 of the compound of formula (1).

[0072] Fig.21 : XRPD comparison diagram of the mesylate salt form D1 of the compound of formula (1) before and after heating.

[0073] Fig. 22 : Thermogravimetric analysis (TGA) diagram of the mesylate crystal form D1 of the compound of formula (1).

[0074] Fig.23 : Differential scanning calorimetry (DSC) diagram of the mesylate crystal form D1 of the compound of formula (1).

[0075] Fig.24 : X-ray powder diffraction (XRPD) pattern of the mesylate crystalline form E of the compound of formula (1).

[0076] Fig.25 : XRPD comparison diagram of the mesylate crystal form E of the compound of formula (1) before and after heating.

[0077] Fig.26 : Thermogravimetric analysis (TGA) of the mesylate crystal form E of the compound of formula (1).

[0078] Fig. 27: Differential scanning calorimetry (DSC) diagram of the mesylate crystalline form E of the compound of formula (1).

[0079] Fig.28 : The mesylate crystal form E of the compound of formula (1) 1 H NMR spectra.

[0080] Fig.29 : X-ray powder diffraction (XRPD) pattern of mesylate crystalline form J of the compound of formula (1).

[0081] Fig.30 : XRPD comparison diagram of the mesylate salt form J of the compound of formula (1) stirred in acetone.

[0082] Fig.31 : X-ray powder diffraction (XRPD) pattern of mesylate crystalline form F of the compound of formula (1).

[0083] Fig.32 : XRPD comparison diagram of the mesylate crystal form F of the compound of formula (1) before and after heating.

[0084] Fig.33 : Thermogravimetric analysis (TGA) of the mesylate form F of the compound of formula (1).

[0085] Fig.34 : Differential scanning calorimetry (DSC) diagram of the mesylate crystalline form F of the compound of formula (1).

[0086] Fig.35 : X-ray powder diffraction (XRPD) pattern of the mesylate crystalline form G of the compound of formula (1).

[0087] Fig.36 : XRPD comparison diagram of the mesylate crystal form G of the compound of formula (1) before and after drying.

[0088] Fig.37 : X-ray powder diffraction (XRPD) pattern of the mesylate crystalline form G1 of the compound of formula (1).

[0089] Fig.38 : XRPD comparison diagram of the mesylate crystal form G1 of the compound of formula (1) before and after heating.

[0090] Fig.39 : X-ray powder diffraction (XRPD) pattern of the mesylate crystal form K of the compound of formula (1).

[0091] Fig.40 : XRPD comparison diagram of the mesylate crystal form K of the compound of formula (1) stirred in acetone.

[0092] Fig.41: Thermogravimetric analysis (TGA) diagram of the mesylate crystal form G1 of the compound of formula (1).

[0093] Fig.42 : Differential scanning calorimetry (DSC) diagram of the mesylate crystal form G1 of the compound of formula (1).

[0094] Fig.43 : X-ray powder diffraction (XRPD) pattern of mesylate crystalline form H of the compound of formula (1).

[0095] Fig.44 : XRPD comparison diagram of the mesylate salt form H of the compound of formula (1) before and after heating.

[0096] Fig.45 : Thermogravimetric analysis (TGA) of the mesylate crystal form H of the compound of formula (1).

[0097] Fig.46 : Differential scanning calorimetry (DSC) diagram of the mesylate crystalline form H of the compound of formula (1).

[0098] Fig.47 : The mesylate crystalline form H of the compound of formula (1) 1 H NMR spectra.

[0099] Fig.48 : X-ray powder diffraction (XRPD) pattern of mesylate crystalline form I of the compound of formula (1).

[0100] Fig.49 : XRPD comparison diagram of the mesylate salt form I of the compound of formula (1) before and after heating.

[0101] Fig.50 : Thermogravimetric analysis (TGA) of the mesylate crystal form I of the compound of formula (1).

[0102] Fig.51 : Differential scanning calorimetry (DSC) diagram of the mesylate crystalline form I of the compound of formula (1).

[0103] Fig.52 : The mesylate crystalline form I of the compound of formula (1) 1 H NMR spectra.

[0104] Fig.53 : XRPD overlay of mesylate crystalline form A, mesylate crystalline form B and mesylate crystalline form D1 of the compound of formula (1).

[0105] Fig.54 : XRPD overlay of mesylate crystalline form C, mesylate crystalline form F and mesylate crystalline form G1 of the compound of formula (1).

[0106] Fig.55 : XRPD overlay of mesylate crystalline form E, mesylate crystalline form H and mesylate crystalline form I of the compound of formula (1).

[0107] Fig.56 : XRPD overlay of mesylate crystalline form D, mesylate crystalline form G, mesylate crystalline form J, mesylate crystalline form K and mesylate crystalline form L of the compound of formula (1).

[0108] Fig.57 : XRPD comparison diagram of suspension competition between mesylate crystalline form A and mesylate crystalline form B of the compound of formula (1).

[0109] Fig.58 : XRPD comparison diagram of suspension competition between mesylate crystalline form B and mesylate crystalline form D1 of the compound of formula (1).

[0110] Fig.59 : Water activity test (aw~0 / 0.248) of mesylate crystalline form B, mesylate crystalline form C, mesylate crystalline form G1 and mesylate crystalline form L of the compound of formula (1).

[0111] Fig.60 : Water activity test of mesylate crystal form B, mesylate crystal form C, mesylate crystal form G1 and mesylate crystal form L of the compound of formula (1) (aw~0.4 / 0.61 / 0.847 / 1.0).

[0112] Fig.61 : XRPD comparison diagram of free form A of the compound of formula (1) before and after stability test.

[0113] Fig.62 : XRPD comparison diagram of the mesylate crystal form B of the compound of formula (1) before and after the stability test.

[0114] Fig.63 : XRPD comparison diagram of the mesylate crystal form C of the compound of formula (1) before and after the stability test.

[0115] Fig.64 : XRPD comparison diagram of the mesylate salt form F of the compound of formula (1) before and after the stability test.

[0116] Fig.65 : DVS test diagram of the mesylate crystal form B of the compound of formula (1).

[0117] Fig.66 : XRPD comparison diagram of the mesylate salt form B of the compound of formula (1) before and after DVS test.

[0118] Fig.67 : DVS test diagram of the mesylate crystal form C of the compound of formula (1).

[0119] Fig.68 : XRPD comparison diagram of the mesylate crystal form C of the compound of formula (1) before and after DVS test.

[0120] Fig.69 : DVS test diagram of the mesylate crystal form F of the compound of formula (1).

[0121] Fig.70 : XRPD comparison diagram of the mesylate salt form F of the compound of formula (1) before and after DVS test. DETAILED DESCRIPTION

[0122] The intermediate compounds of the present application can be prepared by a variety of synthesis methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitution methods well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present application.

[0123] The chemical reactions of the specific embodiments of the present application are carried out in a suitable solvent, which must be suitable for the chemical changes of the present application and the reagents and materials required. In order to obtain the compounds of the present application, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction processes based on the existing embodiments.

[0124] The present application will be described in detail below through examples, which do not imply any limitation to the present application.

[0125] X-ray powder diffraction (XRPD)

[0126] XRPD Testing Parameters

[0127]

[0128] Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC)

[0129] TGA and DSC test parameters

[0130]

[0131] H NMR spectrum ( 1 H NMR)

[0132] 1 H NMR test parameters

[0133]

[0134] Ion Chromatography (IC)

[0135] IC Test Parameters

[0136]

[0137] High Performance Liquid Chromatography (HPLC)

[0138] HPLC test parameters

[0139]

[0140] Dynamic Water Sorption Analysis (DVS)

[0141] DVS test parameters

[0142]

[0143] Example 1: Free Form A of the Compound of Formula (I) (1-(3-cyano-5-methylthiophene-2-yl)-N-(6-methoxy-1H-benzo[d]imidazol-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxamide) and Preparation Method

[0144] (1) Preparation method of compound 3 (ethyl 2-acetyl-4-pentanoate)

[0145]

[0146] Compound 1 (ethyl acetoacetate) (5 g, 38.42 mmol, 1.0 eq) was dissolved in triethylamine (75 mL), and compound 2 (chloroacetone) (3.5 g, 38.42 mmol, 1.0 eq) was added. The reactants were reacted at 110 ° C for 2 hours under nitrogen protection. After concentration, the residue was dissolved in water (100 mL) and then extracted twice with dichloromethane (50 mL each time). The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate = 100 / 1 to 50 / 1 to 20 / 1) to obtain compound 3 (ethyl 2-acetyl-4-pentanoate) (1.3 g, yield: 18.3%) as a colorless oil. MS (ESI) m / z: 187 [M+H + ]TLC: PE / EA(2 / 1); R f (Compound 1) = 0.6; R f (Compound 3) = 0.4.

[0147] (2) Preparation method of compound 5 (1-(3-cyano-5-methylthiophene-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester)

[0148]

[0149] Compound 3 (2-acetyl-4-pentanoic acid ethyl ester) (1 g, 7.23 mmol, 1.0 eq) was dissolved in toluene (20 mL), and compound 4 (2-amino-3-cyano-5-methylthiophene) (1.6 g, 8.68 mmol, 1.2 eq) and p-toluenesulfonic acid (249 mg, 1.45 mmol, 0.2 eq) were added. The reactants were stirred at 110 ° C for 16 hours. The solid was filtered and concentrated. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate = 50 / 1 to 30 / 1) to obtain yellow oily compound 5 (1-(3-cyano-5-methylthiophene-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester) (860 mg, yield: 41%). MS (ESI) m / z: 289 [M+H + ]. TLC: petroleum ether / ethyl acetate (10 / 1); R f (Compound 3) = 0.2; R f (Compound 5) = 0.4.

[0150] (3) Preparation method of free crystal form A of the compound of formula (I)

[0151]

[0152] Trimethylaluminum (0.15 mL, 0.306 mmol, 1.0 eq, 2 M in toluene) was added to compound 5 (ethyl 1-(3-cyano-5-methylthiophene-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxylate) (50 mg, 0.306 mmol, 1.0 eq) and compound 7 (5-methoxy-1H-benzimidazol-2-amine) (88 mg, 0.306 mmol, 1.0 eq) dissolved in 1 mL of toluene. The reactants were stirred at 100°C for 16 hours. The mixture was cooled to room temperature, quenched with methanol (10 mL), and then adjusted to pH 3 with 3 M hydrochloric acid. The mixture was diluted with water (30 mL) and then extracted three times with ethyl acetate, 20 ml each time. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by preparative high pressure liquid phase Prep-HPLC (acetonitrile / water (containing 0.1% formic acid)) to obtain free crystalline form A of the compound of formula (I) (5 mg, yield: 4%). MS (ESI) m / z: 406 [M+H + ]. 1 H NMR (400MHz, DMSO-d6): δ12.04(s,1H),11.20(s,1H),7.32(s,1H),7.29(s,1H),6.98(s,1H ), 6.89 (s, 1H), 6.69 (d, J = 7.2Hz, 1H), 3.73 (s, 3H), 2.47 (s, 3H), 2.38 (s, 3H), 2.04 (s, 3H).

[0153] The free crystalline form A has substantially the following Figure 1 XRPD pattern shown.

[0154] The XRPD pattern of free crystalline form A has characteristic diffraction peaks at the following 2θ angles, as shown in Table 1-1:

[0155] Table 1-1

[0156]

[0157]

[0158] like Figure 2 As shown, the thermogravimetric analysis (TGA) curve of the free crystalline form A shows a weight loss of about 1.02% when the temperature is raised to about 200°C.

[0159] like Figure 3 As shown, the differential scanning calorimetry (DSC) curve of the free crystalline form A has an endothermic peak at about 163°C.

[0160] Example 2: Methanesulfonate crystalline form of the compound of formula (I) and preparation method thereof

[0161] Preparation method of mesylate crystal form A of compound of formula (I)

[0162] About 20 mg of free crystalline form A was weighed into a 3 mL glass vial, 1.2 equivalents (5.78 mg) of methanesulfonic acid (methanesulfonic acid mass content: 99%) was added, 0.5 mL of acetone was added, and the sample was ultrasonically dissolved. After stirring at room temperature for about 2 days, the solid was centrifuged and placed at 25 ° C for 4 hours. The XRPD separation test was the mesylate crystalline form A. This method replaces acetone with isopropanol or acetonitrile, and the mesylate crystalline form A can also be prepared.

[0163] Methanesulfonate Form A has substantially Figure 5 XRPD pattern shown.

[0164] The XRPD pattern of the mesylate salt form A has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-1:

[0165] Table 2-1

[0166]

[0167] like Figure 6 As shown, the thermogravimetric analysis (TGA) curve of the mesylate salt crystal form A shows a weight loss of about 0.34% when the temperature is raised to about 150° C. The mesylate salt crystal form A is an anhydrous substance.

[0168] like Figure 7As shown, the differential scanning calorimetry (DSC) curve of the mesylate salt form A has an endothermic peak at about 246°C, an exothermic peak at about 251°C, and an endothermic peak at about 267°C.

[0169] Preparation method of mesylate crystal form B of compound of formula (I)

[0170] 3500.77 mg of free base crystal form A was weighed and added to a 250 mL single-mouth bottle, and 70 mL of acetone was added, and the mixture was stirred at room temperature. Under stirring, 10 mL of acetone solution containing 673 uL of methanesulfonic acid was slowly added to the single-mouth bottle, and the vial containing acid was rinsed with 2 mL of acetone, and the rinse solution was added to the single-mouth bottle again. The system changed from a turbid liquid to a clear liquid, and solids precipitated after stirring for about 2 hours. After stirring for 3 days, the mixture was filtered, and the filter cake was placed at 40°C and vacuum dried for about 16 hours to obtain 3865.63 mg of mesylate crystal form B.

[0171] Methanesulfonate Form B has substantially Figure 8 XRPD pattern shown.

[0172] The XRPD pattern of mesylate salt form B has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-2:

[0173] Table 2-2

[0174]

[0175] like Fig. 9 As shown, the thermogravimetric analysis (TGA) curve of the mesylate salt crystal form B shows a weight loss of about 0.25% when the temperature is raised to about 150° C. The mesylate salt crystal form B is an anhydrous substance.

[0176] like Fig.10 As shown, the differential scanning calorimetry (DSC) curve of the mesylate salt form B has an endothermic peak at about 273°C.

[0177] The molar ratio of the compound of formula (I) to methanesulfonic acid in the mesylate salt form B is about 1:1.

[0178] Rough solubility of the mesylate salt form B of the compound of formula (I) at room temperature

[0179] Weigh about 2.0 mg of the starting sample into a 3.0 mL vial, add 50 μL (100 μL, 200 μL, 400 μL, 1000 μL, 2000 μL) of the corresponding solvent to dissolve the sample (vortexing and ultrasound to promote sample dissolution) until the sample is dissolved or the volume reaches 2000 μL. V1 is the volume of the sample before dissolution, V2 is the volume of the sample, and S is the rough solubility (N / A means not measured).

[0180]

[0181]

[0182] Preparation method of mesylate crystal form C of compound of formula (I)

[0183] About 200 mg of mesylate crystal form B was weighed and added to a 20 mL vial, and 5 mL of water was added, and ultrasonic dissolution was promoted. The mixture was suspended and stirred at room temperature for 3 days. XRPD was separated and tested, and the result was mesylate crystal form C.

[0184] Methanesulfonate Form C has substantially the following Fig.12 XRPD pattern shown.

[0185] The XRPD pattern of mesylate salt form C has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-3:

[0186] Table 2-3

[0187]

[0188]

[0189] like Fig.16 As shown, the thermogravimetric analysis (TGA) curve of the mesylate salt crystal form C shows a weight loss of about 6.82% when the temperature is raised to about 120° C. The mesylate salt crystal form C is a hydrate crystal form, wherein the ratio of the number of mesylate salt and water molecules of the compound of formula (1) is about 1:2.

[0190] like Fig.17 As shown, the differential scanning calorimetry (DSC) curve of mesylate salt form C has an endothermic peak at about 90°C, an exothermic peak at about 188°C, an endothermic peak at about 230°C, an exothermic peak at about 235°C, a slight endothermic peak at about 252°C, and an endothermic peak at about 272°C.

[0191] like Fig.13 As shown, the mesylate salt form C remains unchanged after being dried with forced air at 40°C for about 16 hours; the crystal is transformed into the mesylate salt form L after the temperature is raised to 155°C and the solvent is removed; the crystal is transformed into the mesylate salt form A after the temperature is raised to 205°C.

[0192] Preparation method of mesylate crystal form L of compound of formula (I)

[0193] The mesylate crystal form C was heated to 155° C. The mesylate crystal form L was separated and tested by XRPD.

[0194] The mesylate salt form L has substantially the following Fig.14 XRPD pattern shown.

[0195] The XRPD pattern of the mesylate salt form L has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-4:

[0196] Table 2-4

[0197]

[0198] The mesylate salt form L is a metastable form. Fig.15 As shown, the mesylate crystal form L showed the diffraction peak of the mesylate crystal form C when it was placed in a closed state at room temperature for 2 hours, and most of it was transformed into the mesylate crystal form C after being placed in a closed state at room temperature for 3 days.

[0199] Preparation method of mesylate crystal form D of compound of formula (I)

[0200] About 100 mg of mesylate crystal form B was weighed and added to a 20 mL vial, and 15 mL of ethanol was added, and sonicated at 50° C., then filtered into a 20 mL vial, and stirred at 5° C. for 3 days. XRPD was separated and tested, which was mesylate crystal form D.

[0201] Methanesulfonate Form D has substantially the following Fig.18 XRPD pattern shown.

[0202] The XRPD pattern of the mesylate salt form D has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-5:

[0203] Table 2-5

[0204]

[0205] Methanesulfonate crystal form D is a metastable crystal form. Fig.19 As shown, the mesylate salt form D is transformed into the mesylate salt form D1 after being dried with forced air at 40°C for about 16 hours.

[0206] Preparation method of mesylate crystal form D1 of compound of formula (I)

[0207] The mesylate crystal form D was placed under 40°C for forced air drying for about 16 hours. The XRPD test showed that the mesylate crystal form D1 was obtained.

[0208] Methanesulfonate Form D1 has substantially Fig. 20 XRPD pattern shown.

[0209] The XRPD pattern of the mesylate salt form D1 has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-6:

[0210] Table 2-6

[0211]

[0212] like Fig. 22 As shown, the thermogravimetric analysis (TGA) curve of the mesylate salt form D1 shows a weight loss of about 0.10% when the temperature is raised to about 150° C. The mesylate salt form D1 is an anhydrous substance.

[0213] like Fig.23 As shown, the differential scanning calorimetry (DSC) curve of the mesylate salt form D1 has a small exothermic peak at about 204°C, an endothermic peak at about 250°C, an exothermic peak at about 254°C, and an endothermic peak at about 271°C.

[0214] like Fig.21 As shown, the mesylate crystal form D1 is heated to 225°C and transformed into a mixed crystal of the mesylate crystal form K and the mesylate crystal form J.

[0215] Preparation method of mesylate crystal form E of compound of formula (I)

[0216] About 100 mg of mesylate crystal form B was weighed and added to a 20 mL vial, and 15 mL of 1,4-dioxane was added, and the mixture was sonicated at 50°C, filtered into a 20 mL vial, and stirred at room temperature for 3 days. The separation test XRPD showed that the mesylate crystal form E was obtained.

[0217] Methanesulfonate Form E has substantially Fig.24 XRPD pattern shown.

[0218] The XRPD pattern of the mesylate salt form E has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-7:

[0219] Table 2-7

[0220]

[0221] like Fig.26 As shown, the thermogravimetric analysis (TGA) curve of the mesylate salt crystal form E shows a weight loss of about 13.58% when the temperature is raised to about 190°C. The mesylate salt crystal form E is a 1,4-dioxane solvate crystal form, in which the molecular ratio of the mesylate salt to the 1,4-dioxane is about 1:1. Fig.28 The middle arrow indicates the 1,4-dioxane solvent peak.

[0222] like Fig. 27 As shown, the differential scanning calorimetry (DSC) curve of the mesylate salt form E has an endothermic peak at about 130°C, an exothermic peak at about 231°C, and an endothermic peak at about 273°C.

[0223] like Fig.25 As shown, the mesylate crystal form E is heated to 190°C to remove the solvent to obtain the mesylate crystal form J.

[0224] Preparation method of mesylate crystal form J of compound of formula (I)

[0225] The mesylate crystal form E was heated to 190° C. The mesylate crystal form J was separated and tested by XRPD.

[0226] Methanesulfonate Form J has substantially the following Fig.29 XRPD pattern shown.

[0227] The XRPD pattern of the mesylate salt form J has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-8:

[0228] Table 2-8

[0229]

[0230] Methanesulfonate crystal form J is a metastable crystal form. Fig.30 As shown, mesylate salt form J is transformed into mesylate salt form B upon stirring in acetone at room temperature for 1 day.

[0231] Preparation method of mesylate crystal form F of compound of formula (I)

[0232] Method 1: Weigh about 20 mg of mesylate Form B into a 3 mL vial, add 0.6 mL of a mixed solvent of water / methanol (v:v 1:3), sonicate at 50°C, filter into a 20 mL vial, and stir at 5°C for 1 day. Separate and test XRPD, which is mesylate Form F.

[0233] Method 2: Weigh about 100 mg of mesylate Form B into a 20 mL vial, add 4 mL of a mixed solvent of water / methanol (v:v 1:5), sonicate at 50°C, filter into a 20 mL vial, and stir at 5°C for 2 hours. Separate and test XRPD, which is mesylate Form F.

[0234] Methanesulfonate Form F has substantially Fig.31 XRPD pattern shown.

[0235] The XRPD pattern of the mesylate salt form F has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-9:

[0236] Table 2-9

[0237]

[0238] like Fig.33 As shown, the thermogravimetric analysis (TGA) curve of the mesylate salt form F shows a weight loss of about 3.17% when the temperature is raised to about 120° C. The mesylate salt form F is a hydrate form, in which the ratio of the number of mesylate salt molecules to the number of water molecules is about 1:1.

[0239] like Fig.34 As shown, the differential scanning calorimetry (DSC) curve of mesylate salt form F has continuous endothermic peaks before about 170°C, an exothermic peak at about 188°C, an endothermic peak at about 248°C, an endothermic peak at about 252°C, and an endothermic peak at about 268°C.

[0240] like Fig.32 As shown, the mesylate salt form F remains unchanged after being dried with forced air at 40°C for about 16 hours; after being heated to 155°C for dehydration and then cooled to room temperature, the crystal form remains unchanged; after being heated to 215°C, the crystal is transformed into a mixed crystal of the mesylate salt form J and the mesylate salt form K.

[0241] Preparation method of mesylate crystal form G of compound of formula (I)

[0242] About 20 mg of mesylate salt form B was weighed and added to a 3 mL vial, and 2 mL of a mixed solvent of methanol / methyl tert-butyl ether (v:v 3:1) was added, and sonicated at 50°C, then filtered into a 3 mL vial, and stirred at 5°C for 1 day. The separation test XRPD showed that the mesylate salt form G was obtained.

[0243] The mesylate salt form G has substantially the following Fig.35 XRPD pattern shown.

[0244] The XRPD pattern of the mesylate salt form G has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-10:

[0245] Table 2-10

[0246]

[0247] The mesylate salt form G is a metastable form. Fig.36 As shown, the mesylate salt form G will transform into the mesylate salt form G1 when dried at room temperature.

[0248] Preparation method of mesylate crystal form G1 of compound of formula (I)

[0249] About 100 mg of mesylate crystal form B was weighed and added to a 20 mL vial, and 7 mL of a mixed solvent of methanol / isopropyl acetate (v:v 3:1) was added, and sonicated at 50°C, and then filtered into a 3 mL vial, stirred at 5°C for 1 day, and then filtered, and the filter cake was dried at 40°C for about 16 hours. The separation test XRPD showed that the mesylate crystal form G1 was obtained.

[0250] Methanesulfonate Form G1 has substantially Fig.37 XRPD pattern shown.

[0251] The XRPD pattern of the mesylate salt form G1 has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-11:

[0252] Table 2-11

[0253]

[0254] like Fig.41As shown, the thermogravimetric analysis (TGA) curve of the mesylate crystal form G1 of the compound of formula (1) shows a weight loss of about 3.73% when the temperature is raised to about 120° C. The mesylate crystal form G1 is a hydrate crystal form, in which the ratio of the number of mesylate and water molecules is about 1:1.

[0255] like Fig.42 As shown, the differential scanning calorimetry (DSC) curve of the mesylate salt form G1 of the compound of formula (1) has continuous endothermic peaks before about 120°C, an endothermic peak at about 152°C, an exothermic peak at about 179°C, an endothermic peak at about 250°C, an exothermic peak at about 254°C, and an endothermic peak at about 273°C.

[0256] like Fig.38 As shown, the mesylate crystal form G1 is heated to 130°C for dehydration and then cooled to room temperature without changing its crystal form; it is heated to 190°C and transformed into the mesylate crystal form K.

[0257] Preparation method of mesylate crystal form K of compound of formula (I)

[0258] The mesylate crystal form G1 was heated to 190° C. The mesylate crystal form K was separated and tested by XRPD.

[0259] The mesylate salt form K has substantially the following Fig.39 XRPD pattern shown.

[0260] The XRPD pattern of the mesylate salt form K has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-12:

[0261] Table 2-12

[0262]

[0263]

[0264] Methanesulfonate crystal form K is a metastable crystal form. Fig.40 As shown, the mesylate salt form K is transformed into the mesylate salt form B upon stirring in acetone at room temperature for 1 day.

[0265] Preparation method of mesylate crystal form H of compound of formula (I)

[0266] About 200 mg of mesylate crystal form B was weighed and added to a 20 mL vial, and 5 mL of a mixed solvent of N-methylpyrrolidone / isopropyl acetate (v:v 1:5) was added, and sonicated and stirred at 5°C for 3 days. XRPD analysis showed that the mesylate crystal form H was obtained.

[0267] The mesylate salt form H has substantially the following Fig.43 XRPD pattern shown.

[0268] The XRPD pattern of the mesylate salt form H has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-13:

[0269] Table 2-13

[0270]

[0271] like Fig.45 As shown, the thermogravimetric analysis (TGA) curve of the mesylate salt form H of the compound of formula (1) shows a weight loss of about 16.15% when the temperature is raised to about 155°C. The mesylate salt form H is a N-methylpyrrolidone solvate form, wherein the molecular ratio of the mesylate salt to the N-methylpyrrolidone is about 1:1. Fig.47 The middle arrow indicates the N-methylpyrrolidone solvent peak.

[0272] like Fig.46 As shown, the differential scanning calorimetry (DSC) curve of the mesylate crystal form H of the compound of formula (1) has an endothermic peak at about 143°C, an endothermic peak at about 156°C, and an endothermic peak at about 272°C.

[0273] like Fig.44 As shown, the mesylate salt form H is heated to 200°C to remove the solvent and transform into the mesylate salt form B.

[0274] Preparation method of mesylate crystal form I of compound of formula (I)

[0275] About 200 mg of mesylate crystal form B was weighed and added to a 20 mL vial, and 5 mL of N,N-dimethylformamide / isopropyl ether (v:v 1:5) was added, and sonicated and suspended and stirred at 5°C for 3 days. The separation test XRPD showed that the mesylate crystal form I was obtained.

[0276] The mesylate salt form I has substantially the following Fig.48 XRPD pattern shown.

[0277] The XRPD pattern of the mesylate salt form I has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2-14:

[0278] Table 2-14

[0279]

[0280] like Fig.50 As shown, the thermogravimetric analysis (TGA) curve of the mesylate salt form I of the compound of formula (1) shows a weight loss of about 11.89% when the temperature is raised to about 180°C. The mesylate salt form I is a N,N-dimethylformamide solvate form, wherein the molecular ratio of the mesylate salt to the N,N-dimethylformamide is about 1:1. Fig.52 The arrow in the figure indicates the N,N-dimethylformamide solvent peak.

[0281] like Fig.51 As shown, the differential scanning calorimetry (DSC) curve of the mesylate salt form I of the compound of formula (1) has an endothermic peak at about 143°C, an endothermic peak at about 147°C, and an endothermic peak at about 272°C.

[0282] like Fig.49 As shown, the mesylate salt form I is heated to 200°C to remove the solvent and transform into the mesylate salt form B.

[0283] Example 3: Suspension competition assay

[0284] To confirm the mutual conversion relationship between mesylate crystal forms A / B / D1, suspension competition tests were conducted in acetone and ethyl acetate systems at room temperature and 50°C, respectively. First, a saturated solution of the starting sample mesylate crystal form B at the corresponding temperature and solvent was prepared. 1) The mesylate crystal form A and mesylate crystal form B samples of equal weight were mixed and added to the filtered saturated solution to form a suspension, and suspended and stirred at room temperature and 50°C for 3 days, respectively; 2) The mesylate crystal form B and mesylate crystal form D1 samples of equal weight were mixed and added to the filtered saturated solution to form a suspension, and suspended and stirred at room temperature and 50°C for 3 days, respectively.

[0285] The results are as follows Fig.57 , Fig.58 As shown in Table 3-1, the physical mixture of mesylate form A / B and the physical mixture of mesylate form B / D1 are both converted into mesylate form B, indicating that in the range of room temperature to 50°C, mesylate form B has higher thermodynamic stability than mesylate form A / D1.

[0286] Table 3-1

[0287]

[0288] Example 4: Water activity study

[0289] The water activity was studied to confirm the mutual conversion relationship between mesylate crystal forms B / C / G1 / L. First, a saturated solution of the starting sample mesylate crystal form B at room temperature and the corresponding solvent was prepared, and then a solid mixture of mesylate crystal form B, mesylate crystal form C, mesylate crystal form G1 and mesylate crystal form L was added. The results showed that at room temperature, the mesylate anhydrate crystal form B was more stable in a water-free system; in the humidity range of water activity Aw<0.4, the mesylate hydrate crystal form F was relatively stable; in the humidity range of water activity Aw≥0.4, the mesylate hydrate crystal form C was relatively stable. The results are as follows Fig.59 , Fig.60 As shown in Table 4-1.

[0290] Table 4-1

[0291]

[0292] Example 5: 24-hour equilibrium solubility experiment in water

[0293] The 24-hour equilibrium solubility of free base crystal form A and mesylate crystal form B was tested. The specific steps are: weigh 10 mg of free base crystal form A and mesylate crystal form B respectively into 1 mL of water to prepare a suspension, stir magnetically at 37±2°C, take samples after 24 hours, centrifuge the samples, and use the obtained solids for XRPD testing. The supernatant is filtered through a 0.22μm PTFE filter membrane and then tested for solubility. The results are shown in Table 5-1. The solubility of mesylate crystal form B is about 13.2μg / mL, which is improved compared to free base crystal form A.

[0294] Table 5-1

[0295] Solid form Equilibrium solubility in water at 37℃ (μg / mL) Free base form A 1.92 Methanesulfonate Form B 13.2

[0296] Example 6: One-week stability experiment

[0297] Free base crystal form A and mesylate crystal form B / C / F samples were placed under 25℃ / 60%RH (long term) and 40℃ / 75%RH (accelerated) conditions for one week, and then tested for HPLC purity and crystal form changes. The results are shown in Table 6-1. After the mesylate crystal form B / C / F was placed under the two test conditions for one week, the HPLC purity and crystal form did not change significantly, and the chemical stability and crystal form stability were both good. The XRPD comparison of the stability sample before and after placement is shown in Table 6-1. Figure 61 to Figure 64 shown.

[0298] Table 6-1

[0299]

[0300] Example 7: Hygroscopicity test

[0301] To evaluate the stability risk of samples at 25°C with humidity changes, DVS tests were performed on mesylate forms B / C / F, and solid samples were collected for XRPD testing. The results are summarized in Table 7-1.

[0302] Under 0-80% RH conditions, the water absorption of mesylate form B is less than 0.2%, and the sample is non-hygroscopic.

[0303] The mesylate salt form C absorbs about 0.363% water at 50-80% RH, dehydrates about 0.510% at 80-20% RH, begins to change more significantly at 20% RH, dehydrates sharply at 20-0% RH, then begins to absorb water rapidly in an environment of 0-40% RH, and absorbs about 0.801% water at 40-80% RH, indicating that the mesylate salt form C is relatively stable in an environment of ≥40% RH.

[0304] The mesylate salt form F absorbs about 0.073% water at 60-80% RH, dehydrates about 0.2212% at 80-20% RH, dehydrates about 0.3599% at 20-0% RH, then absorbs about 0.3936% water at 0-20% RH, and absorbs about 0.2038% water at 20-80% RH. There is no obvious water absorption and dehydration phenomenon during the entire humidity cycle, indicating that the mesylate salt form F has a certain stability in the 0-80% RH humidity environment (it is stable within 6 hours in each humidity stage).

[0305] After DVS testing, the crystal forms of the mesylate crystal forms B / C / F samples did not change significantly (the differences in XRPD were mainly caused by preferred orientation and crystallinity). Figures 65 to 70 shown.

[0306] Table 7-1

[0307]

[0308]

[0309] Example 8: Polymorph screening experiment of the methanesulfonate salt of the compound of formula (1)

[0310] Low temperature 4-8℃ slurry conversion

[0311] About 20 mg of each mesylate crystal form B was weighed into a 3 mL vial, and 0.5 mL of the solvent listed in Table 8-1 was added respectively. The resulting suspension was placed under magnetic stirring at 5°C for about 3 days, and then the solid was collected by centrifugation and subjected to XRPD testing. The test results are shown in Table 8-1.

[0312] Table 8-1

[0313] Solvent, v:v Solid crystal form Tetrahydrofuran Methanesulfonate Form B Water / methanol, 1:1 Methanesulfonate Form C Water / acetone, 1:1 Methanesulfonate Form C n-Heptane / Ethanol, 1:1 Methanesulfonate Form B Ether / 1,4-dioxane, 1:1 Methanesulfonate Form B Dimethyl sulfoxide / ethyl acetate, 1:5 Methanesulfonate Form B Dichloromethane / n-propanol, 1:2 Methanesulfonate Form B

[0314] Room temperature slurry conversion

[0315] About 20 mg of each mesylate crystal form B was weighed into a 3 mL vial, and 0.5 mL of the solvent listed in Table 8-2 was added respectively. The resulting suspension was placed under magnetic stirring at room temperature for about 3 days, and then the solid was collected by centrifugation and subjected to XRPD testing. The test results are shown in Table 8-2.

[0316] Table 8-2

[0317]

[0318]

[0319] *: This sample was directly crystallized into mesylate Form B in acetone and ethyl acetate at room temperature, so no further study was performed.

[0320] High temperature 50℃ slurry conversion

[0321] About 20 mg of each mesylate crystal form B was weighed into a 3 mL vial, and 0.5 mL of the solvent listed in Table 8-3 was added respectively. The resulting suspension was placed at 50° C. and magnetically stirred for about 3 days, and then the solid was collected by centrifugation and subjected to XRPD testing. The test results are shown in Table 8-3.

[0322] Table 8-3

[0323] Solvent, v:v Solid crystal form Ethyl acetate Methanesulfonate Form B Toluene Methanesulfonate Form B Water / isopropyl alcohol, 1:1 Methanesulfonate Form C Water / tetrahydrofuran, 1:1 Methanesulfonate Form C Ethanol / methyl isobutyl ketone, 1:1 Methanesulfonate Form B Ethyl acetate / n-butanol, 1:1 Methanesulfonate Form B n-Propanol / isopropyl ether, 1:1 Methanesulfonate Form B n-Heptane / acetonitrile, 1:1 Methanesulfonate Form B Cyclohexane / isopropyl acetate, 1:1 Methanesulfonate Form B 1,4-Dioxane / isopropanol, 1:1 Methanesulfonate Form B

[0324] Cooling crystallization

[0325] Weigh about 20 mg of each portion of mesylate crystal form B into a 3 mL vial, add a certain volume of the corresponding solvent in Table 8-4, sonicate at 50°C, and filter into another 3 mL vial using a 0.45 μm PTFE filter. Stir the clarified filtrate at 5°C. If solid precipitates, collect the solid by centrifugation and perform XRPD testing. If no solid precipitates, transfer to 50°C for volatilization. The test results are shown in Table 8-4.

[0326] Table 8-4

[0327]

[0328] Cyclic heating and cooling

[0329] Weigh 20 mg of each mesylate crystal form B into a 3 mL vial, add 0.5 mL of the solvent listed in Table 8-5 to dissolve the sample (vortex and ultrasound promote sample dissolution), and record the dissolution status. Add a stirrer and perform cyclic heating and cooling on a magnetic stirrer. The test results are shown in Table 8-5.

[0330]

[0331] Table 8-5

[0332] Solvents Solid crystal form Water / methanol / acetone, 1:1:1 Methanesulfonate Form C Water / tetrahydrofuran / isopropanol, 1:1:1 Methanesulfonate Form C Ethanol / acetone / n-heptane, 1:1:1 Methanesulfonate Form B Methanol / acetonitrile / ethyl acetate, 1:1:1 Methanesulfonate Form B Methyl tert-butyl ether / isopropyl acetate / n-butanol, 1:1:1 Methanesulfonate Form B Dimethyl sulfoxide / ethyl acetate / toluene, 1:2:2 Methanesulfonate Form B N,N-dimethylformamide / methyl tert-butyl ether / acetone, 1:2:2 Methanesulfonate Form B Isopropanol / acetonitrile / 2-methyltetrahydrofuran, 1:1:1 Methanesulfonate Form B Isopropyl ether / ethyl acetate / n-propanol, 1:1:1 Methanesulfonate Form B

Claims

1. A crystalline form of a mesylate salt of a compound of formula (1), wherein the structural formula of the compound of formula (1) is as follows: The mesylate crystalline form is mesylate crystalline form B, mesylate crystalline form C or mesylate crystalline form F; The X-ray powder diffraction pattern of the mesylate salt form B has characteristic diffraction peaks at the following 2θ angles: 8.88±0.2°, 14.85±0.2° and 15.35±0.2°; and its X-ray powder diffraction pattern also has characteristic diffraction peaks at one or more of the following 2θ angles: 7.66±0.2°, 18.84±0.2°, 21.33±0.2°, 21.57±0.2°, 21.99±0.2° and 23.13±0.2°; The X-ray powder diffraction pattern of the mesylate salt form C has characteristic diffraction peaks at the following 2θ angles: 8.07±0.2° and 15.17±0.2°; and its X-ray powder diffraction pattern also has characteristic diffraction peaks at one or more of the following 2θ angles: 7.17±0.2°, 8.63±0.2°, 12.64±0.2°, 17.34±0.2°, 23.51±0.2° and 24.47±0.2°; The X-ray powder diffraction pattern of the mesylate salt form F has characteristic diffraction peaks at the following 2θ angles: 9.60±0.2°, 18.39±0.2° and 19.48±0.2°; and its X-ray powder diffraction pattern also has characteristic diffraction peaks at one or more of the following 2θ angles: 5.88±0.2°, 12.47±0.2°, 27.94±0.2°, 28.27±0.2°, 28.73±0.2° and 37.34±0.2°.

2. The crystalline form according to claim 1, wherein the mesylate salt form B has an XRPD pattern as shown in Figure 8.

3. The crystalline form according to claim 1, wherein the mesylate salt crystalline form C has an XRPD pattern as shown in Figure 12.

4. The crystalline form according to claim 1, wherein the mesylate salt crystalline form F has an XRPD pattern as shown in Figure 31.

5. A pharmaceutical composition comprising the crystalline form according to any one of claims 1 to 4, and one or more pharmaceutically acceptable carriers.

6. Use of the crystalline form according to any one of claims 1 to 4 or the pharmaceutical composition according to claim 5 in the preparation of a medicament for preventing and / or treating lung cancer, lymphoma, glioblastoma, breast cancer, colon cancer or liver cancer.

7. A method for preparing the mesylate crystal form B of the compound of formula (1) as claimed in claim 1, include: An organic solvent is added to the free crystalline form A of the compound of formula (1), and then methanesulfonic acid is added. After stirring at room temperature for 2-5 days, the solid is collected and then dried to obtain the methanesulfonate crystalline form B; the organic solvent is selected from isopropanol, acetone, ethyl acetate, acetonitrile, tetrahydrofuran or dichloromethane.

8. A method for preparing the mesylate crystal form C of the compound of formula (1) as claimed in claim 1, comprising any one of the following methods: (I) adding water or a mixed solvent of water / organic solvent to the mesylate crystalline form B of the compound of formula (1), stirring at room temperature for 2-5 days to obtain the mesylate crystalline form C, wherein the organic solvent is selected from ethanol or 1,4-dioxane, and the volume ratio of water to the organic solvent in the mixed solvent is 1:1; (II) adding a mixed solvent of water / organic solvent to the mesylate salt form B of the compound of formula (1), stirring at 4-8° C. for 2-5 days to obtain the mesylate salt form C, wherein the organic solvent is selected from methanol, n-propanol, acetonitrile or acetone, and the volume ratio of water to the organic solvent in the mixed solvent is 1:1 to 3:1; (III) adding a mixed solvent of water / organic solvent to the mesylate salt form B of the compound of formula (1), stirring at 50° C. for 2-5 days to obtain the mesylate salt form C, wherein the organic solvent is selected from isopropanol or tetrahydrofuran, and the volume ratio of water to the organic solvent in the mixed solvent is 1:

1.

9. A method for preparing the mesylate crystalline form F of the compound of formula (1) as claimed in claim 1, include: A mixed solvent of water / methanol is added to the mesylate crystal form B of the compound of formula (1) to promote dissolution, and then filtered. The filtrate is stirred at 5° C. for 2-24 hours to obtain the mesylate crystal form F. The volume ratio of water to methanol in the mixed solvent is 1:3 to 1:5.